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Lyme disease accounted for more than two-thirds (56 of 81, 
69.1%) of all tick-borne disease referrals to a large, academic 
infectious diseases clinic in a low-incidence state. Deviations 
from diagnostic testing guidelines and errors in test interpreta-
tion were common (23 of 35, 65.7%), suggesting that frontline 
providers need additional clinical support.
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There were nearly 500 000 cases of tick-borne illness (TBI) re-
ported to the Centers for Disease Control and Prevention (CDC) 
from 2004 to 2016, with Lyme disease accounting for 82% of 
cases [1]. More than 90% of Lyme disease cases are acquired 
between northern Virginia and New England. In contrast, 
North Carolina is considered a low-incidence state, consistent 
with the results of multiple clinical studies and entomological 
surveys [2–4]. Despite the low incidence, there is indirect ev-
idence that provider and patient awareness of Lyme disease 
is increasing, resulting in increased care-seeking and testing. 
For example, since 2008, when the “probable” case classifica-
tion was first introduced, the number of reported “confirmed” 
cases (eg, typical erythema migrans [EM] and laboratory evi-
dence of infection and a known exposure to tick environment 
in a low-incidence state OR any case with ≥1 late manifestation 
with laboratory evidence of infection) in North Carolina has re-
mained relatively constant while the number of probable cases 
increased >7-fold [5]. Therefore, we sought to quantify and de-
scribe the population of patients referred to a large academic 
infectious diseases (ID) clinic for TBI in a state with low inci-
dence of Lyme disease.
METHODS
We performed a prospective review of all individuals referred 
to the University of North Carolina ID Clinic for evaluation of 
TBI (n  =  1146). Clinic staff screened incoming referrals and 
flagged those potentially associated with TBI, including those 
referred for fever, arthritis/arthralgia, headache, rash, neurolog-
ical symptoms, rash, fatigue, and “chronic Lyme,” for review by 
study staff. We abstracted demographic information, clinical 
history, and laboratory test results from the available medical 
record and compared characteristics of the cohort using the 
Student t test for continuous variables and Pearson’s chi-square 
or Fisher exact test for categorical variables. In a post hoc anal-
ysis, we categorized errors in diagnostic testing and test inter-
pretation for the subset of patients referred for Lyme disease 
based upon deviations from established guidelines [6]. All data 
were collected in a REDCap database [7]. Statistical analyses 
were performed in Stata 12.1 (College Station, TX, USA). The 
study was approved by the institutional review board of the 
University of North Carolina at Chapel Hill.
RESULTS
From April 1, 2018, to March 31, 2019, we reviewed 81 referrals 
for tick-borne illness, representing 7.1% of all referrals to the 
clinic. The most common referring diagnosis was Lyme disease 
(56 of 81, 69.1%), while referrals for Rocky Mountain spotted 
fever (16 of 81, 19.8%) and ehrlichiosis (7 of 81, 8.6%) were less 
frequent. In addition, 1 patient was referred for babesiosis and 
another for “tick bite.” The majority of referrals were from pri-
mary care providers, most of whom were not affiliated with our 
institution (Table 1). Nearly one-third of patients had been un-
successfully referred to another academic ID clinic before our 
institution, and a significant number had previously been seen 
by another ID specialist.
The largest proportion of referred patients were middle-aged 
(median age [interquartile range {IQR}], 43.5 [33.0–54.5] years), 
Caucasian (39 of 45, 86.7%), and female (41 of 56, 73.2%). More 
than half (33 of 56, 58.9%) carried a comorbid psychiatric di-
agnosis, including 22 (39.3%) with depression, 19 (33.9%) with 
anxiety disorder, and 5 (8.9%) with post-traumatic stress disorder 
or histories of domestic abuse. Approximately 20% (11 of 56) of 
patients referred for Lyme disease were taking opioid medica-
tions for chronic pain, compared with only 4% (1 of 24) of pa-
tients referred for other tick-borne illnesses (P = .07). Fatigue and 
arthralgia were the most commonly listed symptoms, followed by 
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neurological symptoms. Most neurological symptoms were, how-
ever, atypical for Lyme disease, such as paresthesia, dizziness, and 
memory deficits, among others. Only 9 (16.1%) patients reported 
associated skin findings or rash. Five lesions were reported as 
blisters, bruising, eschar, folliculitis, or poison ivy, whereas no le-
sions were described as bullseye or targetoid in nature, and none 
were formally documented as EM.
Diagnostic test results, representing various combinations of 
enzyme immunoassay (EIA) and Western immunoblot (WB), 
were available for 34 of 56 (60.7%) patients. A total of 22 of 34 
(64.7%) had an EIA performed, and of the 11 with a positive or 
equivocal result, all had a reflex WB. In contrast, 12 referrals 
(35.3%) only had WB testing performed. We also identified 3 
patients who had results from commercial labs specializing in 
Lyme diagnostics (eg, IGeneX), but we did not use the alterna-
tive critieria to establish case classification.
About one-quarter (9 of 34, 26.5%) of initial tests were per-
formed within 30  days of the onset of symptoms. One case 
was classified as confirmed (knee effusion positive for Lyme 
by polymerase chain reaction in an individual relocating from 
Pennsylvania), but had already received appropriate treatment 
and was being referred for post-treatment Lyme disease syn-
drome. Another had a positive EIA and IgM immunoblot result 
(ie, ≥2 bands present), but had not traveled, had no tick exposure, 
and the only symptoms were swelling of the wrists in the setting 
of pregnancy. Lastly, there was 1 patient with an IgM-positive WB 
result from 2017, who had been previously treated, who was being 
referred for chronic Lyme disease. All other referrals did not have 
supportive clinical or laboratory evidence to be classified as a case.
Of the 25 tests performed outside of the early period, the me-
dian time to the first test was >1 year after the onset of symp-
toms. A  total of 15 (60%) had an EIA performed, 8 of which 
were positive or equivocal, whereas 10 had a WB performed in 
isolation, none of which were positive. We defined 3 referrals as 
confirmed cases, all of whom had recently resided or traveled 
to high-incidence states. One patient had a positive 2-tier result 
but no travel history or tick exposure, and her symptoms (eg, 
fatigue, memory loss) were not consistent with existing criteria. 
Thus, most patients (21 of 25, 81.0%) did not have compelling 
evidence of infection and were either inappropriately diagnosed 
or referred primarily for education and/or counseling.
We identified a large number of deviations from testing guide-
lines and errors in test interpretation. These included ordering an 
immunoblot without a preceding EIA (14 of 34, 41.2%), consid-
ering the presence of any bands on an immunoblot as a positive re-
sult (11 of 31, 35.5%), and interpreting a positive IgM immunoblot 
result as evidence of infection in the absence of a positive IgG re-
sult when outside the acute period (5 of 25, 20.0%). Overall, 23 of 
35 (65.7%) of all referrals with evaluable test results demonstrated 
at least 1 error in diagnostic test ordering or interpretation.
Of the 45 patients for which treatment decisions were avail-
able, approximately three-quarters (34 of 45, 75.6%) received 
≥1 course of antibiotics. Of note, all individuals reporting a 
rash, even if the description was not consistent with EM, re-
ceived antibiotics. Doxycycline was the most frequently pre-
scribed for a median duration (IQR) of 14 (14–21) days. At least 
11 patients (29.7%) received multiple course of antibiotics, in-
cluding 5 who had been taking various antibiotics for >1 year.
DISCUSSION
Despite relatively low incidence in North Carolina, Lyme dis-
ease is a frequent reason for referral to our ID clinic, accounting 
for more than two-thirds of all tick-related referrals. Most 
Table 1. Provider and Patient Characteristics of Lyme Disease 
Referrals
Referring provider
Medical specialty/setting, No. (%)
Family medicine 27 (48.2)
Internal medicine 14 (25.0)
Urgent care 3 (5.4)
 Neurology 3 (5.4)
 Other 9 (16.1)
Provider qualifications, No. (%)
Medical doctor 40 (72.7)
Physician assistant 8 (14.6)
Nurse practitioner 6 (10.9)
Practice affiliation, No. (%)
Affiliated clinic 9 (16.1)
External clinic 47 (83.9)
Referred patient 
Demographic characteristics, No. (%)
Median age, median (IQR), y 43.5 (33.0–54.5)
Female sex 41 (73.2)
 Caucasian 39 (86.7)a
Resident of North Carolina 52 (92.9)
Insurance coverage, No. (%)
Private insurance 29 (52.7)
 Medicare 10 (18.2)
 Medicaid 7 (12.7)
 Uninsured 3 (5.5)
Other (eg, Tricare) 6 (10.9)
Chief complaint, No. (%)
 Fatigue 26 (46.4)
 Arthralgia 26 (46.4)
Neurological symptoms 16 (28.6)
 Rash 9 (16.1)
 Fever 3 (5.4)
Previous care, No. (%)
Referred to another ID clinic 17 (30.4)
Seen by another ID physician 9 (16.1)
Prior treatment, No. (%)
Received antibiotics 34 (75.6)b
Received doxycycline 26 (78.8)
Duration, median (IQR), d 14 (14–21)
Multiple antibiotic courses 11 (29.7)
Abbreviations: ID, infectious diseases; IQR, interquartile range.
aUnable to determine race in 13 of 56 (23.2%). 
bUnable to determine prior treatment in 11 of 56 (19.6%).
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patients did not have typical symptoms or diagnostic test results 
consistent with past or present Lyme infection and had already 
received an empirical course of treatment, findings similar to a 
report from a higher transmission area [8].
There are a number of reasons that may explain the dis-
proportionate number of Lyme referrals compared with other 
endemic tick-borne illnesses. First, whereas infections with 
Ehrlichia and Rickettsia are common in North Carolina, these 
diseases typically present more acutely. Most patients are 
diagnosed and treated in primary care clinics and emergency 
departments without referral to an infectious diseases clinic 
[4]. Second, Lyme disease has received widespread attention 
in the popular media, driving patient demand for testing, 
treatment, and expert consultation [9]. Third, many clin-
icians are unfamiliar with current diagnostic and manage-
ment guidelines, as evidenced by the high rates of diagnostic 
test misuse and misinterpretation. Fourth, many patients had 
Lyme testing performed as part of an evaluation for unex-
plained symptoms and may simply have wanted additional 
specialist input.
Based on these findings, we believe there are concrete 
changes that can be made to diagnostic testing interfaces to re-
duce errors in test interpretation and minimize misdiagnosis, 
which can sow confusion and distrust of the medical profession. 
First, immunoblot testing should only be available in response 
to a positive or indeterminate enzyme-linked immunoassay 
result. Although this is clearly outlined in current guidelines, 
providers, and especially those using commercial laboratories, 
frequently ordered an immunoblot in isolation. Recently ap-
proved changes in the 2-step serologic testing algorithm could 
diminish use of the immunoblot in favor of sequential EIAs, 
which may reduce confusion in interpreting results [10]. Second, 
we would recommend that, given the poor specificity, labora-
tories not routinely perform IgM immunoblot testing when 
symptoms have been present for >30 days [11, 12]. Lastly, there 
is a clear need for ongoing educational and decision-making 
support among frontline providers, especially as the Infectious 
Diseases Society of America prepares to release updated guide-
lines for the diagnosis and management of Lyme disease. These 
programs should emphasize recommendations such as only 
testing patients with specific neurological symptoms (eg, men-
ingitis, radiculoneuritis, and cranial neuropathies) and not re-
commending additional antibiotics in patients with persistent 
or recurring nonspecific symptoms, as these issues were key 
drivers of our incoming referrals.
Our review is limited by not having access to the complete 
medical record in most cases, only the records accompanying 
the referral. We may also have underestimated the total number 
of TBI-related referrals if they were not associated with diag-
noses specific to tick-borne disease (eg, neutropenia). Finally, 
our principal finding, that a high rate of errors in diagnostic 
test interpretation should not be generalized to reflect general 
practice patterns within the community, provides insight into 
potential drivers of referrals.
In summary, we found that pervasive concern about Lyme 
disease, despite low endemicity, drove referrals to our ID clinic. 
Confusion regarding interpretation and recommended use of 
diagnostic testing was prevalent among the referrals we re-
viewed. These results underscore the need for clear guidelines 
for testing and treatment, as well as improvement in the way the 
test results are displayed. Until better diagnostics for tick-borne 
illness are developed, these measures will support frontline 
clinicians struggling to respond to these often marginalized pa-
tients seeking explanations for nonspecific symptoms such as 
chronic pain and fatigue.
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